Renal cell carcinoma induces interleukin 10 and prostaglandin E(2) production by monocytes

Immunotherapy with interleukin 2 (IL-2) is not an effective anti-cancer treatment in the majority of patients with renal cell carcinoma (RCC), suggesting that the activation of cytotoxic T cells or NK cells may be impaired in vivo in these patients. The production of immunosuppressive factors by RCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Ménétrier-Caux, C, Bain, C, Favrot, M C, Duc, A, Blay, J Y
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362183/
https://www.ncbi.nlm.nih.gov/pubmed/10408703
http://dx.doi.org/10.1038/sj.bjc.6690021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362183/
https://www.ncbi.nlm.nih.gov/pubmed/10408703
http://dx.doi.org/10.1038/sj.bjc.6690021

Ejemplares similares